Zambon, Announces

Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil®

07.08.2025 - 17:58:49

Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients’ lives better, announces the approval by Chinese regulatory authorities and the launch on the Chinese market of the intravenous (IV) formulation of Fluimucil® (N-acetylcysteine). This milestone marks a significant step in the company’s commitment to global therapeutic innovation in respiratory diseases, reflecting its dedicated focus on both clinical research and patient care.

https://www.europeanreview.org/wp/wp-content/uploads/12103-12111-1.pdf
3 Study Details | A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03843541
4 Tang W, Zhu D, Wu F, Xu J-F, Yang J-P, Deng Z-P, Chen X-B, Papi A, Qu J-M Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion: https://www.europeanreview.org/wp/wp-content/uploads/5119-5127.pdf

@ businesswire.com | CA7609751028 ZAMBON